Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, Clinical Trials, FDA Approvals 2023 | Major Companies- Takeda, Sanofi, Johnson & Johnson, Immunovant, UCB S.A., and Others

DelveInsight's, "Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the Chronic Inflammatory Demyelinating Polyneuropathy pipeline drug profiles, including Chronic Inflammatory Demyelinating Polyneuropathy clinical trials and nonclinical stage products. It also covers the Chronic Inflammatory Demyelinating Polyneuropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

• DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Chronic Inflammatory Demyelinating Polyneuropathy treatment.

• The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies include Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies, Inc., CSL Behring, Nihon Pharmaceutical Co., Ltd, Novartis, Grifols Therapeutics LLC, and others.

• Promising Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapies include I10E, TAK-771, Albumin (Human) 25%, United States Pharmacopeia (USP), Fingolimod, NPB-01, and others

• The Chronic Inflammatory Demyelinating Polyneuropathy companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy R&D. The Chronic Inflammatory Demyelinating Polyneuropathy therapies under development are focused on novel approaches to treat/improve Chronic Inflammatory Demyelinating Polyneuropathy.

To explore more information on the latest breakthroughs in the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline treatment landscape of the report, click here @ Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is an autoimmune-mediated inflammatory disease affecting the peripheral nerves and the nerve roots. This disorder is characterized by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves and by immune infiltrates.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs Profile

HYQVIA: Takeda
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a liquid medicine containing Recombinant Human Hyaluronidase and immunoglobulins. It contains immunoglobulins collected from human plasma. The drug is infused under the skin into the fatty subcutaneous tissue. The hyaluronidase part of HYQVIA helps more of the Ig get absorbed into the body. The drug is approved for adults with primary immunodeficiency, and in adults, children and adolescents with PI and with secondary immunodeficiency. While it is in Phase III trial for CIDP.

Rozanolixizumab: UCB S.A.
Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to the human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and Immunoglobulin G (IgG), accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG autoantibodies. The drug is under clinical development with the aim of improving the lives of people with pathogenic IgG-autoantibody-driven autoimmune diseases, including ITP, myasthenia gravis (MG), and CIDP, by driving the removal of pathogenic IgG autoantibodies.

Temelimab: GeNeuro SA
Temelimab is a monoclonal antibody designed to neutralize a pathogenic viral envelope protein, encoded by a member of the Human Endogenous Retrovirus-W family, pHERV-W. This protein is thought to be a causal factor in several diseases, including multiple sclerosis, Type 1 diabetes and CIDP. It neutralizes the pHERV-W Env protein without targeting the patient's immune system, and could be a treatment that is both safe and effective in slowing or stopping the disease's progress in all its forms. By neutralizing pHERV-W env, GNbAC1 could at the same time block these pathological inflammatory processes and restore remyelination in patients. The drug is currently in Phase I trial for the treatment of CIDP patients.

Request a sample and discover the recent advances in Chronic Inflammatory Demyelinating Polyneuropathy Ongoing Clinical Trial Analysis and Medications, click here @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Chronic Inflammatory Demyelinating Polyneuropathy. The companies which have their Chronic Inflammatory Demyelinating Polyneuropathy drug candidates in the most advanced stage, i.e. phase III include, Takeda.

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Segmentation

Phases
DelveInsight's report covers around 12+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

For further information, refer to the detailed Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs, Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers, and Barriers, click here for Chronic Inflammatory Demyelinating Polyneuropathy Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report

• Coverage- Global

• Chronic Inflammatory Demyelinating Polyneuropathy Companies- Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies, Inc., CSL Behring, Nihon Pharmaceutical Co., Ltd, Novartis, Grifols Therapeutics LLC, and others.

• Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapies include I10E, TAK-771, Albumin (Human) 25%, United States Pharmacopeia (USP), Fingolimod, NPB-01, and others

• Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers, click here @ Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Inflammatory Demyelinating Polyneuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Inflammatory Demyelinating Polyneuropathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. HYQVIA: Takeda
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Rozanolixizumab: UCB S.A.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Temelimab: GeNeuro SA
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
21. Chronic Inflammatory Demyelinating Polyneuropathy Key Products
22. Chronic Inflammatory Demyelinating Polyneuropathy- Unmet Needs
23. Chronic Inflammatory Demyelinating Polyneuropathy- Market Drivers and Barriers
24. Chronic Inflammatory Demyelinating Polyneuropathy- Future Perspectives and Conclusion
25. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Views
26. Chronic Inflammatory Demyelinating Polyneuropathy Key Companies
27. Appendix

Got Queries? Find out the related information on Chronic Inflammatory Demyelinating Polyneuropathy Mergers and acquisitions, Chronic Inflammatory Demyelinating Polyneuropathy licensing activities @ Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91 9568243403
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.